Duke University Medical Center, Durham, North Carolina, USA.
Drugs Aging. 2011 Apr 1;28(4):249-55. doi: 10.2165/11586880-000000000-00000.
Chronic non-terminal diseases, including postmenopausal osteoporosis, are associated with poor treatment compliance and persistence. The longer a patient with osteoporosis complies and persists with treatment, the lower the risk of fracture. Retrospective studies with emphasis on real-world data have led to a greater understanding of the factors affecting medication compliance and persistence, and their association with improved treatment outcomes. However, these data do not contain information about patient choices of medication or patient commitment to particular medication regimens. Patient preferences can affect compliance and persistence behaviours. While recent evidence questions the importance of dosing regimen in patient preferences, other recent data show that medication efficacy and safety remain the most important determinants of patient preference. Informed patient decision making about treatment options, adverse effects and outcomes can have a beneficial impact on medication-taking behaviour. Healthcare professionals play a crucial role in the management of factors associated with poor compliance and persistence with osteoporosis therapies. Education about disease consequences and differences among treatment options, as well as treatment monitoring and positive reinforcement, are crucial to improving medication compliance and persistence in osteoporotic patients.
慢性非传染性疾病，包括绝经后骨质疏松症，与治疗依从性和持久性差有关。骨质疏松症患者遵医嘱并坚持治疗的时间越长，骨折的风险就越低。强调真实世界数据的回顾性研究使人们更深入地了解了影响药物依从性和持久性的因素，以及它们与改善治疗结果的关系。然而，这些数据并不包含关于患者选择药物或对特定药物治疗方案的承诺的信息。患者的偏好会影响其用药的依从性和持久性。虽然最近的证据质疑剂量方案对患者偏好的重要性，但其他最近的数据表明，药物的疗效和安全性仍然是患者选择的最重要决定因素。患者对治疗方案、不良反应和结果的知情决策可能对用药行为产生有益影响。医疗保健专业人员在管理与骨质疏松症治疗依从性和持久性差相关的因素方面发挥着关键作用。关于疾病后果和治疗选择差异的教育，以及治疗监测和积极强化，对于提高骨质疏松症患者的药物依从性和持久性至关重要。
